153 related articles for article (PubMed ID: 38492078)
21. Salvage Radiotherapy for Recurrent Prostate Cancer after High-Intensity Focused Ultrasound Therapy: Quality of Life and Functional Outcome.
Cafuta B; Distler FA; Wagner A; Pahernik S; Albrecht C; Hatiboglu G
Urol Int; 2022; 106(9):940-945. PubMed ID: 35104820
[TBL] [Abstract][Full Text] [Related]
22. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
23. Feasibility and safety of definite volumetric modulated arc therapy with simultaneous integrated boost to the dominant intraprostatic lesion in patients with unfavorable intermediate to high-risk prostate cancer.
Dankulchai P; Sittiwong W; Teerasamit W
Rep Pract Oncol Radiother; 2022; 27(2):260-267. PubMed ID: 36299386
[TBL] [Abstract][Full Text] [Related]
24. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
[TBL] [Abstract][Full Text] [Related]
25. Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer.
Reinikainen P; Lehtinen I; Luukkaala T; Kellokumpu-Lehtinen PL
Anticancer Res; 2024 Jan; 44(1):139-150. PubMed ID: 38159980
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients.
Petersen SE; Thorsen LB; Hansen S; Petersen PM; Lindberg H; Moe M; Petersen JB; Muren LP; Høyer M; Bentzen L
Acta Oncol; 2022 Feb; 61(2):179-184. PubMed ID: 34543143
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
Alayed Y; Davidson M; Liu S; Chu W; Tseng E; Cheung P; Vesprini D; Cheung H; Morton G; Musunuru HB; Ravi A; Korol R; Deabreu A; Ho L; Commisso K; Bhounr Z; D'Alimonte L; Mittmann N; Dragomir A; Zhang L; Loblaw A
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):136-142. PubMed ID: 31987962
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
31. Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes.
Guimond E; Lavallée MC; Foster W; Vigneault É; Guay K; Martin AG
Radiother Oncol; 2019 Apr; 133():62-67. PubMed ID: 30935583
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
33. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
[TBL] [Abstract][Full Text] [Related]
34. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
Buwenge M; Alitto AR; Cilla S; Capocaccia I; Mazzeo E; Ippolito E; Mantini G; Siepe G; Cavallini L; Valentini V; Deodato F; Morganti AG; Macchia G
Anticancer Res; 2020 Nov; 40(11):6499-6503. PubMed ID: 33109589
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
37. Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.
Buergy D; Schneiberg V; Schaefer J; Welzel G; Trojan L; Bolenz C; Wenz F
Health Qual Life Outcomes; 2018 Jan; 16(1):21. PubMed ID: 29357874
[TBL] [Abstract][Full Text] [Related]
38. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
39. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
40. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
